EXPERIMENTAL ALZHEIMER'S DRUG COULD COME FROM A PARTNERING DEAL WITH ASTRAZENECA

May 07, 2014

By Jane Brown

Share on

Potentially good news for research into Alzheimer’s Disease.  AstraZeneca is said to be talking to other pharmaceutical companies as it seeks a partnering deal for its experimental Alzheimer’s drug.  Briggs Morrison, global head of medicines development, says a deal would share development of AstraZeneca’s so called BACE inhibitor drug, which is set to enter late stage Phase 3 development.  AstraZeneca believes its BACE inhibitor could potentially sell as much as $5 billion a year, but it gives only a 9 percent chance of success on a risk adjusted basis given the high failure rate in the disease sector. The British Company is fighting a $106 billion bid approach from fellow drug giant Pfizer.

Join Our Fan Club
Coverage Area
Downtown Toronto
96.7FM
Toronto HD
96.3 HD-2
Kingston to Windsor, Parry Sound to Pittsburgh
AM740
ZoomerRadio Logo

Recently Played: